Shopping Cart 0
Cart Subtotal
USD 0

Novelion Therapeutics Inc (NVLN) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Novelion Therapeutics Inc (NVLN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novelion Therapeutics Inc (Novelion), formerly QLT Inc, is a biopharmaceutical company that focuses on the development and commercialization of products and solutions for the treatment of people living with rare diseases. The company's two marketed products are Lomitapide, a small molecule microsomal triglyceride transfer protein inhibitor offered under the brand name JUXTAPID, and Metreleptin, a recombinant analog of human leptin offered under the brand name MYALEPT. It also possesses another product candidate, zuretinol acetate, an oral synthetic retenoid for use in treatment of inherited retinal disease. The company operates along with its subsidiaries across North America, South America, Europe and Asia. Novelion is headquartered in Vancouver, British Columbia, Canada.

Novelion Therapeutics Inc Key Recent Developments

Jul 12,2018: EdgePoint Investment Group Acquires Shares of Common Stock of Novelion Therapeutics

Jul 03,2018: Novelion Therapeutics Names Mark Corrigan As Executive Chair Of The Board Of Directors

May 10,2018: Novelion Therapeutics Reports First Quarter 2018 Financial Results

Mar 15,2018: Novelion Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results

Feb 28,2018: Novelion Therapeutics Observes Rare Disease Day

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Novelion Therapeutics Inc-Key Facts 6

Novelion Therapeutics Inc-Key Employees 7

Novelion Therapeutics Inc-Key Employee Biographies 8

Novelion Therapeutics Inc-Major Products and Services 9

Novelion Therapeutics Inc-History 10

Novelion Therapeutics Inc-Company Statement 12

Novelion Therapeutics Inc-Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Section 2-Company Analysis 16

Company Overview 16

Novelion Therapeutics Inc-Business Description 17

Product Category: Lomitapide 17

Overview 17

Performance 17

Product Category: Metreleptin 17

Overview 17

Performance 18

Geographical Segment: Brazil 18

Performance 18

Geographical Segment: Other Foreign countries 18

Performance 18

Geographical Segment: The US 18

Performance 18

R&D Overview 18

Novelion Therapeutics Inc-SWOT Analysis 19

SWOT Analysis-Overview 19

Novelion Therapeutics Inc-Strengths 19

Novelion Therapeutics Inc-Weaknesses 20

Novelion Therapeutics Inc-Opportunities 21

Novelion Therapeutics Inc-Threats 22

Novelion Therapeutics Inc-Key Competitors 23

Section 3-Company Financial Ratios 24

Financial Ratios-Capital Market Ratios 24

Financial Ratios-Annual Ratios 25

Performance Chart 28

Financial Performance 28

Financial Ratios-Interim Ratios 29

Financial Ratios-Ratio Charts 30

Section 4-Company's Lifesciences Financial Deals and Alliances 31

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

Novelion Therapeutics Inc, Recent Deals Summary 33

Section 5-Company's Recent Developments 34

May 10, 2018: Novelion Therapeutics Reports First Quarter 2018 Financial Results 34

Feb 28, 2018: Novelion Therapeutics Observes Rare Disease Day 35

Jan 30, 2018: Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals 36

Jan 24, 2018: Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review 37

Dec 04, 2017: Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer 38

Nov 21, 2017: Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice 39

Nov 09, 2017: Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change 40

Oct 31, 2017: Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer 42

Oct 12, 2017: Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D 43

Sep 11, 2017: Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors 44

Section 6-Appendix 45

Methodology 45

Ratio Definitions 45

About GlobalData 49

Contact Us 49

Disclaimer 49


List Of Figure

List of Figures

Novelion Therapeutics Inc, Performance Chart (2013-2017) 28

Novelion Therapeutics Inc, Ratio Charts 30

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32


List Of Table

List of Tables

Novelion Therapeutics Inc, Key Facts 6

Novelion Therapeutics Inc, Key Employees 7

Novelion Therapeutics Inc, Key Employee Biographies 8

Novelion Therapeutics Inc, Major Products and Services 9

Novelion Therapeutics Inc, History 10

Novelion Therapeutics Inc, Other Locations 14

Novelion Therapeutics Inc, Subsidiaries 14

Novelion Therapeutics Inc, Key Competitors 23

Novelion Therapeutics Inc, Ratios based on current share price 24

Novelion Therapeutics Inc, Annual Ratios 25

Novelion Therapeutics Inc, Annual Ratios (Cont...1) 26

Novelion Therapeutics Inc, Annual Ratios (Cont...2) 27

Novelion Therapeutics Inc, Interim Ratios 29

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

Novelion Therapeutics Inc, Recent Deals Summary 33

Currency Codes 45

Capital Market Ratios 45

Equity Ratios 46

Profitability Ratios 46

Cost Ratios 47

Liquidity Ratios 47

Leverage Ratios 48

Efficiency Ratios 48

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Novelion Therapeutics Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Regeneron Pharmaceuticals Inc

Mimetogen Pharmaceuticals Inc

Genentech Inc

ASKA Research

Novelion Therapeutics Inc (NVLN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novelion Therapeutics Inc (Novelion), formerly QLT Inc, is a biopharmaceutical company that focuses on the development and commercialization of products and solutions for the treatment of people living with rare diseases. The company's two marketed products are Lomitapide, a small molecule microsomal triglyceride transfer protein inhibitor offered under the brand name JUXTAPID, and Metreleptin, a recombinant analog of human leptin offered under the brand name MYALEPT. It also possesses another product candidate, zuretinol acetate, an oral synthetic retenoid for use in treatment of inherited retinal disease. The company operates along with its subsidiaries across North America, South America, Europe and Asia. Novelion is headquartered in Vancouver, British Columbia, Canada.

Novelion Therapeutics Inc Key Recent Developments

Jul 12,2018: EdgePoint Investment Group Acquires Shares of Common Stock of Novelion Therapeutics

Jul 03,2018: Novelion Therapeutics Names Mark Corrigan As Executive Chair Of The Board Of Directors

May 10,2018: Novelion Therapeutics Reports First Quarter 2018 Financial Results

Mar 15,2018: Novelion Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results

Feb 28,2018: Novelion Therapeutics Observes Rare Disease Day

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Novelion Therapeutics Inc-Key Facts 6

Novelion Therapeutics Inc-Key Employees 7

Novelion Therapeutics Inc-Key Employee Biographies 8

Novelion Therapeutics Inc-Major Products and Services 9

Novelion Therapeutics Inc-History 10

Novelion Therapeutics Inc-Company Statement 12

Novelion Therapeutics Inc-Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Section 2-Company Analysis 16

Company Overview 16

Novelion Therapeutics Inc-Business Description 17

Product Category: Lomitapide 17

Overview 17

Performance 17

Product Category: Metreleptin 17

Overview 17

Performance 18

Geographical Segment: Brazil 18

Performance 18

Geographical Segment: Other Foreign countries 18

Performance 18

Geographical Segment: The US 18

Performance 18

R&D Overview 18

Novelion Therapeutics Inc-SWOT Analysis 19

SWOT Analysis-Overview 19

Novelion Therapeutics Inc-Strengths 19

Novelion Therapeutics Inc-Weaknesses 20

Novelion Therapeutics Inc-Opportunities 21

Novelion Therapeutics Inc-Threats 22

Novelion Therapeutics Inc-Key Competitors 23

Section 3-Company Financial Ratios 24

Financial Ratios-Capital Market Ratios 24

Financial Ratios-Annual Ratios 25

Performance Chart 28

Financial Performance 28

Financial Ratios-Interim Ratios 29

Financial Ratios-Ratio Charts 30

Section 4-Company's Lifesciences Financial Deals and Alliances 31

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

Novelion Therapeutics Inc, Recent Deals Summary 33

Section 5-Company's Recent Developments 34

May 10, 2018: Novelion Therapeutics Reports First Quarter 2018 Financial Results 34

Feb 28, 2018: Novelion Therapeutics Observes Rare Disease Day 35

Jan 30, 2018: Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals 36

Jan 24, 2018: Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review 37

Dec 04, 2017: Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer 38

Nov 21, 2017: Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice 39

Nov 09, 2017: Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change 40

Oct 31, 2017: Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer 42

Oct 12, 2017: Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D 43

Sep 11, 2017: Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors 44

Section 6-Appendix 45

Methodology 45

Ratio Definitions 45

About GlobalData 49

Contact Us 49

Disclaimer 49


List Of Figure

List of Figures

Novelion Therapeutics Inc, Performance Chart (2013-2017) 28

Novelion Therapeutics Inc, Ratio Charts 30

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32


List Of Table

List of Tables

Novelion Therapeutics Inc, Key Facts 6

Novelion Therapeutics Inc, Key Employees 7

Novelion Therapeutics Inc, Key Employee Biographies 8

Novelion Therapeutics Inc, Major Products and Services 9

Novelion Therapeutics Inc, History 10

Novelion Therapeutics Inc, Other Locations 14

Novelion Therapeutics Inc, Subsidiaries 14

Novelion Therapeutics Inc, Key Competitors 23

Novelion Therapeutics Inc, Ratios based on current share price 24

Novelion Therapeutics Inc, Annual Ratios 25

Novelion Therapeutics Inc, Annual Ratios (Cont...1) 26

Novelion Therapeutics Inc, Annual Ratios (Cont...2) 27

Novelion Therapeutics Inc, Interim Ratios 29

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

Novelion Therapeutics Inc, Recent Deals Summary 33

Currency Codes 45

Capital Market Ratios 45

Equity Ratios 46

Profitability Ratios 46

Cost Ratios 47

Liquidity Ratios 47

Leverage Ratios 48

Efficiency Ratios 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Novelion Therapeutics Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Regeneron Pharmaceuticals Inc

Mimetogen Pharmaceuticals Inc

Genentech Inc

ASKA Research